LogicBio Therapeutics, Inc.

NasdaqGM:LOGC 株式レポート

時価総額:US$68.2m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

LogicBio Therapeutics バランスシートの健全性

財務の健全性 基準チェック /56

主要情報

37.7%

負債資本比率

US$5.93m

負債

インタレスト・カバレッジ・レシオn/a
現金US$30.78m
エクイティUS$15.74m
負債合計US$22.86m
総資産US$38.60m

財務の健全性に関する最新情報

Recent updates

LogicBio jumps 648% on buyout deal with AstraZeneca unit Alexion

Oct 03

Bullish: Analysts Just Made A Notable Upgrade To Their LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Forecasts

Aug 20
Bullish: Analysts Just Made A Notable Upgrade To Their LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Forecasts

LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

Aug 18
LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

LogicBio GAAP EPS of -$0.15, revenue of $3.2M

Aug 15

Is LogicBio Therapeutics (NASDAQ:LOGC) Weighed On By Its Debt Load?

Jan 11
Is LogicBio Therapeutics (NASDAQ:LOGC) Weighed On By Its Debt Load?

Does LogicBio Therapeutics (NASDAQ:LOGC) Have A Healthy Balance Sheet?

Aug 18
Does LogicBio Therapeutics (NASDAQ:LOGC) Have A Healthy Balance Sheet?

LogicBio EPS misses by $0.06, beats on revenue

May 10

LogicBio announces agreements with CANbridge Pharma and Daiichi Sankyo

Apr 27

Is LogicBio Therapeutics (NASDAQ:LOGC) Using Debt Sensibly?

Apr 12
Is LogicBio Therapeutics (NASDAQ:LOGC) Using Debt Sensibly?

Is LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Popular Amongst Insiders?

Mar 08
Is LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Popular Amongst Insiders?

The LogicBio Therapeutics (NASDAQ:LOGC) Share Price Has Gained 12% And Shareholders Are Hoping For More

Jan 15
The LogicBio Therapeutics (NASDAQ:LOGC) Share Price Has Gained 12% And Shareholders Are Hoping For More

LogicBio extends collaboration with Children's Medical Research Institute

Jan 07

LogicBio Therapeutics names new CFO

Dec 22

Looking In On LogicBio

Nov 17

LogicBio reports Q3 results

Nov 09

財務状況分析

短期負債: LOGC's short term assets ($32.8M) exceed its short term liabilities ($16.4M).

長期負債: LOGC's short term assets ($32.8M) exceed its long term liabilities ($6.4M).


デット・ツー・エクイティの歴史と分析

負債レベル: LOGC has more cash than its total debt.

負債の削減: Insufficient data to determine if LOGC's debt to equity ratio has reduced over the past 5 years.


貸借対照表


キャッシュ・ランウェイ分析

過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。

安定したキャッシュランウェイ: LOGC has sufficient cash runway for more than a year based on its current free cash flow.

キャッシュランウェイの予測: LOGC has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 15.8% each year.


健全な企業の発掘